Monday, August 15, 2022
HomeWeekly RoundupEC approves Roche's lung cancer drug in combo Tx

EC approves Roche's lung cancer drug in combo Tx

Roche has received European Commission approval for its Tecentriq drug in combination with Avastin and chemotherapy as an initial treatment for people with a specific type of lung cancer, the Swiss pharma company is quoted in Reuters Health as saying.

The combination has been approved as a first-line treatment for people with metastatic non-squamous non-small cell lung cancer (NSCLC).

NSCLC is the most common type of lung cancer, accounting for about 85% of all cases, Roche said.

[link url=""]Reuters Health report[/link]

Subscribe to our Newsletter

Receive Medical Brief's free weekly e-newsletter.

* indicates required